See more : Zhejiang Cfmoto Power Co.,Ltd (603129.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Duopharma Biotech Berhad (7148.KL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Duopharma Biotech Berhad, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- NTN Corporation (6472.T) Income Statement Analysis – Financial Results
- W&E Source Corp. (WESC) Income Statement Analysis – Financial Results
- Northern Star Investment Corp. III (NSTC-WT) Income Statement Analysis – Financial Results
- Air China Limited (0753.HK) Income Statement Analysis – Financial Results
- DatChat, Inc. (DATS) Income Statement Analysis – Financial Results
Duopharma Biotech Berhad (7148.KL)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://duopharmabiotech.com
About Duopharma Biotech Berhad
Duopharma Biotech Berhad, an investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. The company offers consumer healthcare products comprising vitamins and supplements, analgesics, eyecare, antacids, and skin care products; and generic drugs for various therapeutic classes, such as cardiovascular, dermatology, hormones, respiratory, sensory and nervous system, musculo-skeletal system, anti-infectives, and others. It also provides specialty pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables to patients with conditions, such as diabetes, cancer, cardiovascular diseases, renal diseases, and others. The company's product portfolio comprises vascor, acetan, covasc, crystorvas, bezartan, vytan, and vytocor; insugen and basalog one; kytron, zuhera, lebreta, trevive, and krabeva; and unihepa, ranofer, erysaa, bi-haemosol, and haemosol. The company offers its products under the Champs, Flavettes, Eye Glo, Proviton, Naturalle, and Uphamol brands. In addition, it offers property management and services; and distributes, imports, and exports chemical products. The company was formerly known as CCM Duopharma Biotech Berhad and changed its name to Duopharma Biotech Berhad in February 2019. The company was founded in 1978 and is headquartered in Kuala Lumpur, Malaysia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 704.73M | 696.72M | 639.18M | 569.90M | 576.46M | 498.72M | 467.99M | 312.94M | 269.79M | 176.96M | 162.41M | 135.31M | 138.13M | 131.44M | 123.77M | 122.87M | 115.55M | 105.10M |
| Cost of Revenue | 436.40M | 416.90M | 385.19M | 336.70M | 344.40M | 294.24M | 281.10M | 168.81M | 140.88M | 95.33M | 95.51M | 72.36M | 74.85M | 71.94M | 61.88M | 62.24M | 52.20M | 48.15M |
| Gross Profit | 268.33M | 279.82M | 253.98M | 233.20M | 232.07M | 204.48M | 186.89M | 144.13M | 128.91M | 81.63M | 66.90M | 62.95M | 63.29M | 59.50M | 61.89M | 60.63M | 63.35M | 56.95M |
| Gross Profit Ratio | 38.08% | 40.16% | 39.74% | 40.92% | 40.26% | 41.00% | 39.93% | 46.06% | 47.78% | 46.13% | 41.19% | 46.52% | 45.81% | 45.27% | 50.01% | 49.34% | 54.83% | 54.19% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.49M | 10.26M | 9.70M | 6.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 78.86M | 79.68M | 71.13M | 69.66M | 69.53M | 62.17M | 50.20M | 44.41M | 35.04M | 16.57M | 12.95M | 12.33M | 12.04M | 9.57M | 9.83M | 9.70M | 11.40M | 9.09M |
| Selling & Marketing | 103.86M | 106.91M | 94.65M | 81.16M | 85.82M | 75.66M | 78.48M | 64.89M | 43.06M | 16.72M | 17.13M | 11.30M | 13.25M | 12.27M | 11.38M | 14.22M | 9.11M | 9.67M |
| SG&A | 187.46M | 186.59M | 165.78M | 150.81M | 155.35M | 137.83M | 128.67M | 109.30M | 78.10M | 33.29M | 30.08M | 23.62M | 25.29M | 21.83M | 21.21M | 23.92M | 20.51M | 18.76M |
| Other Expenses | 0.00 | 813.00K | -661.00K | 531.00K | 518.00K | 1.08M | 500.00K | 2.04M | 626.00K | 1.57M | -3.37M | 3.73M | 3.40M | 2.74M | 2.90M | 1.78M | 1.90M | 1.55M |
| Operating Expenses | 187.46M | 187.40M | 165.12M | 151.35M | 155.35M | 140.28M | 133.06M | 111.34M | 78.73M | 34.86M | 26.71M | 27.35M | 28.69M | 24.58M | 24.11M | 25.69M | 22.40M | 20.31M |
| Cost & Expenses | 623.86M | 604.30M | 550.31M | 488.05M | 499.75M | 434.52M | 414.16M | 280.15M | 219.61M | 130.19M | 122.22M | 99.71M | 103.54M | 96.52M | 85.98M | 87.93M | 74.60M | 68.46M |
| Interest Income | 2.75M | 1.52M | 1.20M | 1.51M | 1.46M | 2.11M | 2.72M | 4.23M | 1.38M | 165.00K | 295.00K | 101.00K | 364.00K | 490.00K | 432.00K | 402.00K | 1.59M | 1.45M |
| Interest Expense | 18.20M | 9.10M | 6.44M | 6.53M | 7.96M | 7.55M | 5.00M | 5.34M | 3.61M | 438.00K | 307.00K | 401.00K | 231.00K | 490.00K | 432.00K | 402.00K | 1.59M | 1.45M |
| Depreciation & Amortization | 43.05M | 36.20M | 31.96M | 29.07M | 26.85M | 24.73M | 24.12M | 22.50M | 21.53M | 8.27M | 7.79M | 6.97M | 5.97M | 5.30M | 5.09M | 4.75M | 4.60M | 0.00 |
| EBITDA | 124.00M | 130.63M | 121.91M | 112.43M | 105.96M | 92.12M | 81.16M | 59.53M | 73.10M | 55.21M | 48.27M | 42.67M | 40.93M | 40.22M | 42.87M | 39.69M | 45.55M | 36.64M |
| EBITDA Ratio | 17.60% | 18.61% | 19.01% | 19.61% | 18.25% | 18.44% | 17.28% | 18.96% | 27.05% | 31.20% | 29.72% | 31.54% | 29.63% | 30.60% | 34.64% | 32.30% | 39.42% | 34.86% |
| Operating Income | 80.87M | 92.91M | 88.76M | 81.86M | 77.65M | 65.28M | 54.32M | 32.80M | 50.19M | 46.77M | 40.19M | 35.60M | 34.60M | 34.92M | 37.78M | 34.94M | 40.95M | 36.64M |
| Operating Income Ratio | 11.48% | 13.34% | 13.89% | 14.36% | 13.47% | 13.09% | 11.61% | 10.48% | 18.60% | 26.43% | 24.74% | 26.31% | 25.04% | 26.57% | 30.53% | 28.43% | 35.44% | 34.86% |
| Total Other Income/Expenses | -17.60M | -8.06M | -5.78M | -5.70M | -6.84M | -5.62M | -5.85M | -1.32M | -2.36M | -273.00K | -12.00K | -300.00K | 133.00K | 490.00K | 432.00K | 402.00K | 1.59M | 1.97M |
| Income Before Tax | 63.27M | 84.85M | 82.98M | 76.16M | 70.81M | 59.67M | 51.77M | 31.48M | 47.83M | 46.50M | 40.18M | 35.30M | 34.73M | 35.41M | 38.22M | 35.34M | 42.54M | 38.09M |
| Income Before Tax Ratio | 8.98% | 12.18% | 12.98% | 13.36% | 12.28% | 11.96% | 11.06% | 10.06% | 17.73% | 26.28% | 24.74% | 26.09% | 25.14% | 26.94% | 30.88% | 28.76% | 36.82% | 36.25% |
| Income Tax Expense | 10.62M | 14.74M | 17.30M | 17.55M | 15.54M | 12.03M | 9.31M | 4.65M | 11.44M | 11.23M | 7.90M | 9.28M | 8.02M | 6.74M | 7.98M | 7.94M | 10.50M | 9.12M |
| Net Income | 52.65M | 70.11M | 65.68M | 58.61M | 55.27M | 47.64M | 42.46M | 26.83M | 36.39M | 35.28M | 32.28M | 26.01M | 26.71M | 28.67M | 30.23M | 27.40M | 32.04M | 28.98M |
| Net Income Ratio | 7.47% | 10.06% | 10.28% | 10.28% | 9.59% | 9.55% | 9.07% | 8.57% | 13.49% | 19.93% | 19.87% | 19.23% | 19.33% | 21.81% | 24.43% | 22.30% | 27.73% | 27.57% |
| EPS | 0.05 | 0.07 | 0.07 | 0.06 | 0.06 | 0.05 | 0.05 | 0.03 | 0.06 | 0.06 | 0.06 | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | 0.05 |
| EPS Diluted | 0.05 | 0.07 | 0.07 | 0.06 | 0.06 | 0.05 | 0.05 | 0.03 | 0.06 | 0.06 | 0.06 | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | 0.05 |
| Weighted Avg Shares Out | 958.51M | 948.31M | 928.34M | 923.63M | 893.63M | 874.57M | 867.87M | 867.87M | 627.40M | 582.62M | 582.62M | 582.62M | 582.62M | 582.62M | 582.62M | 582.61M | 582.45M | 582.31M |
| Weighted Avg Shares Out (Dil) | 958.51M | 948.31M | 928.34M | 923.63M | 893.63M | 874.57M | 867.87M | 867.87M | 627.40M | 582.62M | 582.62M | 582.62M | 582.62M | 582.62M | 582.62M | 582.61M | 582.53M | 582.40M |
Source: https://incomestatements.info
Category: Stock Reports